Lilly Zyprexa Marketing Info Sought By Philadelphia U.S. Attorney
Executive Summary
Lilly's antipsychotic Zyprexa is among the drugs targeted in the Philadelphia U.S. Attorney's ongoing probe into prescription drug marketing practices
You may also be interested in...
Off-Label Use “Predictions” May Be Scrutinized, Prosecutor Sheehan Says
Companies may include predictions of off-label use in their business plans but should be careful not to cross the line into encouraging off-label promotion, Philadelphia Associate U.S. Attorney James Sheehan suggested at a Food and Drug Law Institute advertising conference in Washington, D.C
Off-Label Use “Predictions” May Be Scrutinized, Prosecutor Sheehan Says
Companies may include predictions of off-label use in their business plans but should be careful not to cross the line into encouraging off-label promotion, Philadelphia Associate U.S. Attorney James Sheehan suggested at a Food and Drug Law Institute advertising conference in Washington, D.C
Cephalon Marketing Under Investigation By Philadelphia U.S. Attorney
The Philadelphia U.S. Attorney's investigation into Cephalon's marketing practices covers the entire commercial life of Provigil